Page 11 - Peter Greenleaf News Today : Breaking News, Live Updates & Top Stories | Vimarsana

14.7 million in net revenue for the third quarter 2021 Steady increases in LUPKYNIS Patient Start Forms, Conversion Rates and Payer Coverage Addition of two preclinical assets with potential in rare autoimmune conditions to grow and diversify the pipeline Conference call to be hosted today at 8:30 a.m. ET Aurinia Pharmaceuticals Inc. today issued its financial results for the third quarter ended September 30, 2021. ...

AUPH earnings call for the period ending September 30, 2021.

Assets expand immunology portfolio to include B-cell therapy and macrophage modulation - - IND-enabling studies are ongoing and will support the transition of these assets to clinical development in 20222023 - Aurinia Pharmaceuticals Inc. today announced the addition of two novel assets that will expand the Company’s rare autoimmune and kidney-related disease pipeline. “Over the past year, in anticipation of ...

Aurinia Reports First Quarter 2021 Financial Results and Recent Operational Highlights Over 250 patient start forms received by the end of the first quarter – – Cash and cash equivalents, and investments of $360.9 million at March 31, 2021 – – Conference call to be hosted today at 5:00 p.m. ET – Aurinia Pharmaceuticals Inc. today issued its financial results for the first quarter ended March 31, 2021. Amounts, unless specified otherwise, are expressed in U.S. dollars. “2021 started with the FDA … – Over 250 patient start forms received by the end of the first quarter – �...

- Cash, cash equivalents, and investments of $423 million at December 31, 2020 - Victoria, BC, March 3, 2021--(T-Net)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) today issued its financial results for the fourth quarter and year ended December 31, 2020. Amounts, unless specified otherwise, are expressed in U.S. dollars. "Over the past year, Aurinia matured into a fully-integrated biopharmaceutical company with capabilities spanning R&D, clinical, regulatory, CMC, and commercial. The recent FDA approval and immediate launch of LUPKYNIS underscores the exemplary performance and ex...